Karina J. Matissek

发表

The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2013, Molecular pharmaceutics.

Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.

Mohanad Mossalam, Carol S. Lim, J. E. Constance, 2012, Molecular pharmaceutics.

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

K. Ross, S. Ramaswamy, M. Lawrence, 2021, Clinical Cancer Research.

Delivery of a Monomeric p53 Subdomain with Mitochondrial Targeting Signals from Pro-Apoptotic Bak or Bax

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2014, Pharmaceutical Research.

Direct induction of apoptosis using an optimal mitochondrially targeted p53.

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2012, Molecular pharmaceutics.

Re-engineered p53 Activates Apoptosis In Vivo and Causes Primary Tumor Regression in A Dominant Negative Breast Cancer Xenograft Model

M. Salama, Abood Okal, Carol S. Lim, 2014, Gene Therapy.

Re-Engineered p53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity

T. Cheatham, Abood Okal, Carol S. Lim, 2014, Molecular pharmaceutics.

A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.

Andrew S. Dixon, Mohanad Mossalam, Abood Okal, 2013, Molecular pharmaceutics.

Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2012 .

Choosing Targets for Gene Therapy

Carol S. Lim, James R. Davis, Karina J. Matissek, 2011 .

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Maristela L Onozato, A. Iafrate, M. Onozato, 2017, Cancer discovery.

Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.

Mohanad Mossalam, Carol S. Lim, Jonathan E Constance, 2012, Molecular pharmaceutics.